Saturday, February 21, 2026
19.1 C
Bengaluru

Ashok Nair, Managing Director of Abbott India in Conversation with MedicinMan

https://www.credoweb.in/discussion/661/new-growth-drivers-for-indian-pharma-companies

Ashok Nair began his career as a Medical Rep and rose to become the Managing Director of one of India’s most admired pharma companies – Abbott India.

In this conversation, Ashok Nair shares his perspectives on the challenges ahead and what Indian Pharma needs to do, to face them effectively.

Register now to receive your invitation to the webinar on 1st May 2021

Over 20 pharma leaders have shared their perspectives on various aspects of pharma business, you can register and view them at any time on

www.credoweb.in

Hot this week

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich

When a new cancer drug shows promise, it trends...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Topics

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They...

THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL

How a niche Indian topicals manufacturer outgrew its CDMO...

Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?

Transparency, Trust, and the Problem of “Invisible Evidence” in...
spot_img

Related Articles

spot_imgspot_img